公开(公告)号：US20250020660A1

公开(公告)日：2025-01-16

申请号：US18426232

申请日：2024-01-29

Applicant: Biogen MA Inc.

Inventor： Meena Subramanyam ,  Lakshimi Amaravadi ,  Eric Wakshull ,  Frances Lynn ,  Michael Panzara ,  Robin McDaid Barbour ,  Julie Elizabeth Taylor

IPC: G01N33/68 ,  C07K16/28

Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).

公开(公告)号：US20240425573A1

公开(公告)日：2024-12-26

申请号：US18707366

申请日：2022-11-02

Applicant: Biogen MA Inc.

Inventor： Laura Nisenbaum ,  Tianle Chen ,  Raj Rajagovindan

IPC: C07K16/18 ,  A61K39/00 ,  A61P25/28 ,  G01N33/68

Abstract: Provided are methods for treating Alzheimer's disease in a human subject in need thereof comprising administration of an anti-beta-amyloid antibody (e.g., aducanumab) to the subject.

公开(公告)号：US12162952B2

公开(公告)日：2024-12-10

申请号：US17050353

申请日：2019-04-25

Applicant: Biogen MA Inc. ,  Neurimmune AG

Inventor： Jan Grimm ,  Fabio Montrasio ,  Isin Dalkilic-Liddle ,  Mia Marie Rushe ,  Joseph Walter Arndt

IPC: C07K16/00 ,  A61K47/68 ,  A61K49/00 ,  A61K51/10 ,  C07K16/44 ,  G01N33/53

Abstract: Provided are novel dipeptide repeat (DPR) specific antibodies (e.g., human-derived antibodies) as well as synthetic variants and biotechnological derivatives thereof, capable of binding C9orf72 poly-glycine-alanine DPRs, as well as methods and uses related thereto. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.

公开(公告)号：US20240343733A1

公开(公告)日：2024-10-17

申请号：US18576940

申请日：2022-07-07

Applicant: BIOGEN MA INC. ,  C4 THRAPEUTICS, INC.

Inventor： Kevin M. Guckian ,  Emily Anne Peterson ,  Fang Gao ,  Ryan Evans ,  Eric Stefan ,  Jeremy L. Yap ,  Corey Don Anderson ,  Morgan Welzel O'Shea ,  Jae Young M. Ahn ,  Christopher G. Nasveschuk ,  James A. Henderson

IPC: C07D487/04 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/519 ,  C07D401/14 ,  C07D471/04 ,  C07D487/10 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/519 ,  C07D401/14 ,  C07D471/04 ,  C07D487/10 ,  C07D519/00

Abstract: This disclosure relates to compounds of Formula (A): IRAK-L-DSM (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches IRAK to DSM; and IRAK is an IRAK4 binding moiety represented by Formula (I) that is covalently attached to linker L; in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of IRAK4 proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of IRAK4 proteins. The present disclosure also provides methods of treating disorders responsive to modulation of IRAK4 activity and/or degradation of IRAK4 with at least one compound described herein.

公开(公告)号：US20240327380A1

公开(公告)日：2024-10-03

申请号：US18019540

申请日：2021-08-05

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Isaac Marx ,  Jürgen Schulz ,  Harold George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Martin Himmelbauer ,  Vatee Pattaropong ,  John Howard Jones ,  Rab Gilfillan ,  Edward Yin Shiang Lin ,  Felix Gonzalez Lopez de Turiso ,  Bin Ma

IPC: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/10

CPC classification number: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/10

Abstract: Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.

公开(公告)号：US20240216330A1

公开(公告)日：2024-07-04

申请号：US18285123

申请日：2022-04-01

Applicant: BIOGEN MA INC.

Inventor： Michael Joseph Palte ,  Brian T. Hopkins ,  Matthew P. Scaramozza ,  Michael Christian Mingueneau ,  Alex Pellerin ,  Chelsea R. Parker Harp ,  Catherine Barbey

IPC: A61K31/4015 ,  A61K31/225 ,  A61K31/4545 ,  A61K31/4985 ,  A61K31/506 ,  A61P25/28 ,  A61P37/00

CPC classification number: A61K31/4015 ,  A61K31/225 ,  A61K31/4545 ,  A61K31/4985 ,  A61K31/506 ,  A61P25/28 ,  A61P37/00

Abstract: The present disclosure provides combination therapies for treating an autoimmune disease in a subject in need thereof. The methods comprise administering to the subject an effective amount of a BTK inhibitor in combination with an effective amount of a fumaric acid ester (FAE). The autoimmune disease can be treated include, for example, multiple sclerosis (MS), lupus, rheumatoid arthritis (RA), Pemphigus Vugaris (PV), neuromyelitis optica (NMO), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), anti-NMDA receptor encephalitis, or Sjogren's disease.

公开(公告)号：US20240158494A1

公开(公告)日：2024-05-16

申请号：US18490319

申请日：2023-10-19

Applicant: Biogen MA Inc.

Inventor： Isin Dalkilic-Liddle ,  Benjamin A. Smith ,  Karl J.M. Hanf ,  Fang Qian ,  R. Blake Pepinsky ,  Thomas O. Cameron

IPC: C07K16/28 ,  C12N15/113

CPC classification number: C07K16/28 ,  C12N15/113 ,  C07K2317/565

Abstract: The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of their use. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.

公开(公告)号：US11884737B2

公开(公告)日：2024-01-30

申请号：US17361393

申请日：2021-06-29

Applicant: UCB BIOPHARMA SRL ,  BIOGEN MA INC.

Inventor： Ruth Oliver ,  Miren Zamacona

IPC: C07K16/02 ,  A61K39/395 ,  A61P37/06 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to a method of treating an autoimmune or inflammatory disease or a neurodegenerative disease with an antibody to CD154.

公开(公告)号：US11697670B2

公开(公告)日：2023-07-11

申请号：US16640755

申请日：2018-08-22

Applicant: Biogen MA Inc.

Inventor： Matthew Westoby ,  Greg Evangelist

IPC: C07K1/14 ,  C07K1/36 ,  C07K16/00 ,  C07K1/18 ,  C07K1/20 ,  C07K1/22 ,  C07K16/06 ,  A61K39/395

CPC classification number: C07K1/18 ,  A61K39/39591 ,  C07K1/14 ,  C07K1/20 ,  C07K1/22 ,  C07K1/36 ,  C07K16/00 ,  C07K16/065

Abstract: Provided herein, in some embodiments, are methods and compositions for purifying antibodies from cellular cultures using one or more thiol containing additives during a purification process, for example in a chromatographic purification process.

公开(公告)号：US20230174511A1

公开(公告)日：2023-06-08

申请号：US17883202

申请日：2022-08-08

Applicant: Viracta Therapeutics, Inc. ,  Biogen MA Inc.

Inventor： Brian T. HOPKINS ,  Timothy R. CHAN ,  Tracy J. JENKINS ,  Patrick CONLON ,  Xiongwei CAI ,  Michael HUMORA ,  Xianglin SHI ,  Ross A. MILLER ,  Andrew THOMPSON

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton’s tyrosine kinase and which exhibit desirable characteristics for the same.